These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38321619)

  • 1. Antimicrobial Guanidinylate Polycarbonates Show Oral In Vivo Efficacy Against Clostridioides Difficile.
    Xue M; Chakraborty S; Gao R; Wang S; Gu M; Shen N; Wei L; Cao C; Sun X; Cai J
    Adv Healthc Mater; 2024 Jun; 13(14):e2303295. PubMed ID: 38321619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycarbonates with Potent and Selective Antimicrobial Activity toward Gram-Positive Bacteria.
    Nimmagadda A; Liu X; Teng P; Su M; Li Y; Qiao Q; Khadka NK; Sun X; Pan J; Xu H; Li Q; Cai J
    Biomacromolecules; 2017 Jan; 18(1):87-95. PubMed ID: 28064500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bis-Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile.
    Li C; Teng P; Peng Z; Sang P; Sun X; Cai J
    ChemMedChem; 2018 Jul; 13(14):1414-1420. PubMed ID: 29768720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradable antimicrobial polycarbonates with unexpected activity and selectivity for treating multidrug-resistant Klebsiella pneumoniae lung infection in mice.
    Yang C; Lou W; Zhong G; Lee A; Leong J; Chin W; Ding B; Bao C; Tan JPK; Pu Q; Gao S; Xu L; Hsu LY; Wu M; Hedrick JL; Fan W; Yang YY
    Acta Biomater; 2019 Aug; 94():268-280. PubMed ID: 31129359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.
    Tanaka Y; Tashiro S; Ikegami S; Enoki Y; Taguchi K; Matsumoto K
    Anaerobe; 2023 Dec; 84():102789. PubMed ID: 37879532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
    Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial Activity of Tannic Acid
    Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
    Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection.
    Abutaleb NS; Seleem MN
    Sci Rep; 2020 May; 10(1):7701. PubMed ID: 32382070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 11. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
    Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
    Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Genome Sequencing Reveals the High Nosocomial Transmission and Antimicrobial Resistance of Clostridioides difficile in a Single Center in China, a Four-Year Retrospective Study.
    Wen X; Shen C; Xia J; Zhong LL; Wu Z; Ahmed MAEE; Long N; Ma F; Zhang G; Wu W; Luo J; Xia Y; Dai M; Zhang L; Liao K; Feng S; Chen C; Chen Y; Luo W; Tian GB
    Microbiol Spectr; 2022 Feb; 10(1):e0132221. PubMed ID: 35019676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aryl-alkyl-lysines: Novel agents for treatment of C. difficile infection.
    Ghosh C; AbdelKhalek A; Mohammad H; Seleem MN; Haldar J
    Sci Rep; 2020 Mar; 10(1):5624. PubMed ID: 32221399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance in Clostridioides difficile.
    O'Grady K; Knight DR; Riley TV
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2459-2478. PubMed ID: 34427801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.
    Putsathit P; Hong S; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; McGlinchey A; Moore CV; Nimmo GR; Prendergast L; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR
    J Antimicrob Chemother; 2021 Jun; 76(7):1815-1821. PubMed ID: 33895826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
    Takeda S; Miki T
    Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.
    Dureja C; Olaitan AO; Hurdle JG
    Curr Opin Microbiol; 2022 Apr; 66():63-72. PubMed ID: 35077947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile.
    Pu M; Cho JM; Cunningham SA; Behera GK; Becker S; Amjad T; Greenwood-Quaintance KE; Mendes-Soares H; Jones-Hall Y; Jeraldo PR; Chen J; Dunny G; Patel R; Kashyap PC
    Gastroenterology; 2021 Feb; 160(3):941-945.e8. PubMed ID: 33197449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile.
    Murray B; Wolfe C; Marra A; Pillar C; Shinabarger D
    J Antimicrob Chemother; 2020 Aug; 75(8):2149-2155. PubMed ID: 32285102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.